Key result
Circulating levels of the cell adhesion biomarker CHI3L1 strongly predicted adverse clinical outcomes in chronic heart failure (HR 2.27; 95% CI 1.66-3.16 per SD difference).
Why the study?
Cellular adhesion molecules are considered to play a key role in cardiovascular inflammation and vascular endothelial dysfunction in CHF, prompting evaluation of their temporal patterns.
Do circulating biomarkers of cell adhesion predict clinical outcomes in patients with chronic heart failure?
Population
263 ambulant patients with CHF
Comparison
Temporal patterns and levels of 12 blood biomarkers of cell adhesion
Design
Prospective cohort study
Follow-up
Median 2.2 (1.4-2.5) years
Authors
Loading...
May refine HF risk stratification; hypothesis-generating pending prospective validation.
Cohort (n=263)
Do circulating biomarkers of cell adhesion predict clinical outcomes in patients with chronic heart failure?
Hazard Ratio: 2.27 (95% CI 1.66–3.16)
Serial measurements of cell adhesion biomarkers, notably CHI3L1, JAM-A, and C1qR, independently predict adverse clinical outcomes in patients with chronic heart failure.
Bouwens et al. (2020) conducted a cohort in chronic heart failure (n=263). Circulating biomarkers of cell adhesion (e.g., CHI3L1) was evaluated on composite of cardiovascular mortality, HF hospitalization, heart transplantation and implantation of a left ventricular assist device (HR 2.27, 95% CI 1.66-3.16). Circulating levels of the cell adhesion biomarker CHI3L1 strongly predicted adverse clinical outcomes in chronic heart failure (HR 2.27; 95% CI 1.66-3.16 per SD difference).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: